Detection of Airways Obstruction for Cystic Fibrosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to identify hidden, small airway blockages in individuals with cystic fibrosis, even when standard lung tests show normal results. It includes both children and adults with cystic fibrosis who do not exhibit airway issues during routine checks. Participants should have cystic fibrosis with normal lung function tests before using a bronchodilator, a medicine that helps open airways. This observational study does not require any treatment. Individuals with cystic fibrosis and typically normal lung test results may be suitable candidates for this trial. As an unphased trial, it offers a unique opportunity to enhance understanding of cystic fibrosis without requiring treatment.
Do I need to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to consult with the trial coordinators for guidance.
Why are researchers excited about this trial?
Researchers are excited about this trial because it aims to uncover hidden small airways obstruction in people with cystic fibrosis, a condition often managed with medications like bronchodilators, mucolytics, and antibiotics. Unlike treatments that focus on relieving symptoms, this trial could lead to earlier detection of lung issues that aren't easily visible with current methods. By identifying these obstructions early, doctors might be able to intervene sooner and possibly prevent further lung damage. This proactive approach could revolutionize how cystic fibrosis is monitored and managed, improving long-term health outcomes for patients.
Who Is on the Research Team?
Arthur Gelb, MD
Principal Investigator
University of California, Los Angeles
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Retrospective Analysis
Retrospective analysis of pre bronchodilator spirometry and lung CT study to detect abnormal FEF75% in the presence of normal spirometry and FEF25-75.
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- No Treatment Required
Find a Clinic Near You
Who Is Running the Clinical Trial?
Gelb, Arthur F., M.D.
Lead Sponsor
The Hospital for Sick Children
Collaborator
Miller Children's & Women's Hospital Long Beach
Collaborator
Stony Brook University
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.